United States & Eli Lilly and Company
24 shared events · Importance 12 · Last updated Jul 02, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
United States: The United States is involved in a fragile truce with Iran and its economy is showing slower-than-expected growth and elevated consumer prices, leading to potential interest rate hikes by the United States — Federal Reserve.
Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
Domestic
United States: The United States is the primary focus of RaiseMe's efforts, as the nonprofit seeks to mitigate potential catastrophic job losses and economic destabilization within the country due to the rapid advancement of artificial intelligence.
Eli Lilly and Company: Eli Lilly is an employer involved in the RaiseMe project, contributing to the nonprofit's goal of adapting the workforce to an AI economy.
Jun 25, 2026 · 7 articles
Domestic
United States: The United States economy faces uncertainty due to new tariffs, with potential for higher inflation, dampened hiring, and increased costs for consumers and businesses.
Eli Lilly and Company: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Tech
United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.
Eli Lilly and Company: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
International
United States: The United States is involved in escalating tensions with Iran, which has impacted oil prices and contributed to inflation concerns, leading to potential interest rate hikes by the United States — Federal Reserve.
Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.
Jun 03, 2026 · 191 articles
Business
United States: The United States is the target market for Grey Matters Health Inc.'s expansion of neuroimaging clinics, addressing a growing demand for Alzheimer's detection and treatment within the country.
Eli Lilly and Company: Eli Lilly and Company developed Kisunla, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Sep 10, 2025 · 6 articles
Regulatory
Eli Lilly and Company: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
Domestic
Eli Lilly and Company: Eli Lilly and Company saw gains that helped offset drops in other sectors, contributing to the overall positive market performance.
Dec 11, 2025 · 7 articles
Tech
Eli Lilly and Company: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
Tech
Eli Lilly and Company: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how United States and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard